Emerging data also suggest that SGLT2 inhibitors may limit epicardial adipose tissue inflammation and its paracrine impact on atrial myocardium—an increasingly recognized contributor to AF substrate formation [203,207,208]. This evidence concerns the gene SLC5A2 and atrial fibrillation.